TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change from baseline in Local Plaque Severity Index (LPSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Platelet Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cognitive performance assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: urinary homovanillic acid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Initiation of Treatment for Opioid Dependence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Engagement in Treatment for Opioid Dependence
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Response rate to Campath-1H alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to combined treatment with Campath-1H and chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of the combination therapy evaluated by dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Myocardial Lipid Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fecal incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Wound Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration time curve from Hour 0 to infinity (AUC0-∞) of SCH 900800
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (Cmax) of SCH 900800
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of episodes of AF, atypical atrial flutter or left sided atrial tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Soft Tissue Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SUVmax (Maximal Standardized Uptake Value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length for age of the infant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight for length of the infant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight for age of the infant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of the ARGOS-IO pressure sensor
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of the ARGOS-IO pressure sensor
Endpoint domain: Adverse events/effects
Primary endpoint: Performance of the ARGOS-IO system compared to manometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of bleeding episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time taken to return to work (RTW)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean Daily Agreement (Percent of Sensor Values Within 30% of Reference Value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sketching accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sketch speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Photosensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in ICIQ-SF total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant engagement and retention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intervention adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area under the plasma concentration-time curve from 0 to 72 hours (AUC0-72)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve maximum plasma concentration (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in stroke volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Y Balance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline disability level due to dementia at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline cognitive function impairment due to dementia at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Subjects Reporting Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Worry levels as measured by the Penn State Worry Questionnaire (PSWQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Negative beliefs about uncontrollability of thoughts and danger as measured by the Meta Cognitions Questionnaire (MCQ-30)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hours of Services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Receipt of adequate services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to Receipt of Services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Amount of Time to Complete Assessment and Plan
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Accuracy of Written Assessment and Plan in Terms of Control and Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cyanide concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization or >50% of Serum ALT Levels From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Incidence of congenital heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hemodynamic significance of patent ductus arteriosus (PDA) and patent Foramen Ovale (PFO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Radiographic progression free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: safety parameters and adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: clinical lab testing, vital signs, electrocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysphagia Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAV on invasive coronary studies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time of Oxygen Saturation Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to 1% Saturation Drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Causality of adverse events to BPA
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic parameters for boron uptake prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache severity rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mitochondrial gene activation pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body composition improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Refluxes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Occurrence of study related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Long term mortality
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Grade 3/4 Diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality or infectious disease causing consultation or admission
Endpoint domain: Mortality/survival
Primary endpoint: incidence of acute urine retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number and type of micro-aggressions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of urine color
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine haemoglobin content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urocrit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of best corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receiver-operator-curve area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastrointestinal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Global evaluation of pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post-operative cognitive dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuro-cognitive Competence in Daily Living
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Use of Compensatory Cognitive Strategies
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive-related Instrumental Activities of Daily Living (IADL)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change from baseline in 6 Minute Walk Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of granulocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Chimerism measured on total nucleated cells and lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Presence of dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Presence of sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ventilation status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of anti citrullinated peptide antibodies positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Implant Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of advanced adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of patients detected with 3 or more adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of Atrial Fibrillation Requiring Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Atrial Fibrillation Lasting Longer Than 30 Seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Observed ACR level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in auditory hallucination severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Insulin Lispro Area Under the Concentration Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Restoration of useful vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: attention-memory score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Occurrence of chronic pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Percentage of Participants Reporting Pain With Injection of Propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Pain Associated With Injection of Propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Milk plasma ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Diversion Activity Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Perceived Risk of Harm Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Intentions to Divert Prescription Stimulants Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Modified Clinical Global Impression Scale (CGIS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in days of migraine attack per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase of left ventricle outflow tract velocity time integral (LVOT VTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sexual risk
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: psychological empowerment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adenomas size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adenomas location
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response Ratio of Gabapentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Podocan level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wnt Pathway molecule levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in arterial blood volume flow in the bypass graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Pain Scale Ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Oswestry low back pain disability questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lumbar range of motion-Modified Schober test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regional brain tissue oxygen saturation (rSO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Variation of peak systolic velocity of the brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in International Prostate Symptoms Score (IPSS-(S))
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Partial renal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Complete renal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: total number of cholangitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: number of native liver survivors
Endpoint domain: Mortality/survival
Primary endpoint: Number of ante or post-natal diagnosis premolars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotics prescription rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum plasma concentration (Cmax) of cadazolid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum plasma concentration (tmax) of cadazolid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC(0-144h)) of cadazolid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event free survival at day 14
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of subjects with at least 75% improvement in hemangioma extent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GIP, glucose, insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Burden of COPD
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in Hepatic venous pressure gradient (HVPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Platelet Aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence and severity of treatment emergent AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Median Time Between Surgery Date and Start Date Compression
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With at Least One Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants That Withdrew Due to Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate of laparoscopic gastric surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Submandibular fossa depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tolerability of cangrelor regimens
Endpoint domain: Adverse events/effects
Primary endpoint: Insulin daily doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DEPITAC's 10 item screen score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in liver function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urine test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: successful tube placement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Peak plasma insulin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma VE-cadherin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial microparticle levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in TC, LDL-C, HDL-C, Triglycerides, and Fasting blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence of moderate hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of severe hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Patients With Available Step Count Data at Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Available Step Count Data Post-procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-tlast) for Regorafenib and Its Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Drug Excreted Via Urine (0-24 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean relative change in Serum Ferritin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Wound Healing Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Great Saphenous vein patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Operation Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Healthy Eating Index Score (HEI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of grade 3 or higher immune-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Adverse Events Through 30 Days After Dosing
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Serious Adverse Events Through 30 Days After Dosing
Endpoint domain: Adverse events/effects
Primary endpoint: The Occurrence of Increased Toxicity Grade From Baseline as Determined by Laboratory Evaluations
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Trough Serum Concentrations of Motavizumab (MEDI-524)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who experience a grade 2 adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of selected heavy metals in venous blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difference in mean PaO2 values after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Difference in mean PaO2/FiO2 ratio values after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incident overweight or obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes